UBS maintains a Buy rating on Aritzia Inc, highlighting its potential as a long-term earnings growth stock driven mainly by US expansion, digital growth, and margin improvement. The brokerage forecasts 15% revenue and 26% EPS compound annual growth rates through fiscal 2031, with about 85% of incremental revenue expected from the US market. International expansion is viewed as a longer-term opportunity beyond 2031. UBS identifies upcoming Q2 2027 earnings and an October Investor Day as key catalysts that could boost investor confidence and stock performance, especially after concerns about near-term sales normalization caused a valuation dip.
Chewy will report its Q2 2026 earnings on September 9, with analysts expecting earnings per share (EPS) of $0.36, a 9.1% increase year-over-year, and revenue of $3.32 billion, up 6.8%. Growth is driven by its Autoship subscription program and expansi...
Tarsus Pharmaceuticals recently acquired Alkeus Pharmaceuticals, gaining worldwide rights to gildeuretinol, a promising Phase 3 drug for Stargardt's disease, which currently lacks FDA-approved treatments. Analyst Jefferies raised Tarsus' price target...
The Trade Desk is undergoing restructuring with a 15% workforce reduction costing up to $51 million, following its removal from the S&P 500 index which caused a 2% stock drop. Despite these challenges, the company shows strong financial health, repor...
GameStop reported Q2 2026 revenue of $790.20 million, beating analyst estimates but showing a 19% year-over-year decline due to a strong prior year and strategic store closures. The company's Collectibles segment grew 57% to $356.30 million, offsetti...
Raymond James analyst Michael Freeman raised Dyne Therapeutics' price target to $37, suggesting an 80.75% upside from its current price around $20.60. The clinical-stage biotech is advancing treatments for muscle diseases like Myotonic Dystrophy Type...
